

Oliver Marx moving from Medartis AG in Basel to become Chief Sales Officer at Syntellix AG

- **Oliver Marx (50) is taking up a new position at Syntellix AG in Hanover on 1 May 2020**
- **He will be responsible for national and international sales and will report directly to Syntellix's boss, Prof. Dr. Utz Claassen (56)**
- **Mr. Marx has outstanding experience and an excellent track record in the field of medical technology, both in terms of sustained dynamic growth and credibility and contacts worldwide, as well as with regard to a hugely successful international IPO**
- **Syntellix's CEO Claassen says: "The magnesium age has dawned."**

Hanover, 28 April 2020.

Syntellix AG, the global biomaterials pioneer and leading provider of highly innovative magnesium implants for orthopaedics and trauma surgery, has appointed Oliver Marx as its new Chief Sales Officer (CSO). Mr. Marx will be responsible for global sales and will report directly to the company's CEO, Prof. Dr. Utz Claassen. He will be taking up his position at Syntellix AG in Hanover on 1 May 2020.

Mr. Marx can look back on a highly successful 20-year career with market-leading companies that operate globally in the med-tech sector. He has an extensive wealth of experience and has been active for more than 15 years in leading positions and strategic corporate management. During this time, he has achieved the demonstrably successful expansion, development and restructuring of international sales structures in the core markets of Europe and Asia, the USA, the world's largest med-tech market, and the emerging markets of Latin America and the APAC region. All this makes him a globally respected specialist in the sales and marketing of medical technology products and a unique authority in the med-tech products scene. Most recently, Mr. Marx was Chief Sales Officer (CSO) and Member of the Executive Board of Medartis AG in Basel, where he also oversaw and was jointly responsible for the successful IPO of Medartis Holding AG.

At Syntellix AG — also as CSO — Mr. Marx will drive forward the displacement of conventional implants made of titanium and polylactide by Syntellix's patented MAGNEZIX® technology, which is superior in many aspects and offers benefits to patients. He will also be closely involved in the final phase of preparations for the planned IPO in Singapore. Syntellix's CEO Prof. Dr. Utz Claassen says: "With Mr. Marx, we are pleased to have gained an internationally renowned sales and industry professional who is unrivalled in Europe. The fact that he is moving from a much larger company in the same function to us and our advanced products shows that he shares our enthusiasm for the MAGNEZIX® technology

Syntellix AG
Aegidientorplatz 2a
30159 Hannover
Germany

T +49 511 270 413 50
F +49 511 270 413 79

info@syntellix.com
www.syntellix.com

Executive Board
Prof. Dr. rer. pol.
Utz Claassen
Chairman of the Executive
Board/CEO

Dr. rer. pol. oec.
Amir S. Ghoreishi
CFO

Prof. Dr. med.
Martin Kirschner
CTO

Chair of the Supervisory
Board
Annette Claassen

Registered Office
Hannover
Amtsgericht Hannover
HRB 202618

For further information:
Pierre Frega
press@syntellix.com

Disclaimer:

This press release is a translation and has been issued for information purposes only. Should there be any discrepancy between this translation and the original German text, the latter shall be the legally binding version.

and its great and diverse benefits for doctors and patients, and is a clear confirmation of our mission. The magnesium age has dawned.”

With Mr. Marx’s participation, Syntellix will be pressing ahead and focusing on the rigorous expansion and continuous and rapid development of markets and cooperation with clinics and doctors in order to ensure that the future-oriented beneficial magnesium technology, which offers additional safety to patients and the operating theatre environment, especially in times of infection pandemics, gains its rightful place in the field of osteology. Syntellix already has MAGNEZIX® product approvals in a total of 65 countries worldwide — for the treatment of malpositions, fractures and cartilage-bone defects using the most advanced magnesium implants in orthopaedic, trauma, paediatric and sports surgery.

About Syntellix:

Syntellix AG based in Hanover, Germany, is an international company engaged in biomedical engineering and material & life science that is undergoing dynamic organic growth. The company specialises in the research, development and marketing/sales of highly innovative transformable metallic implants. These are broken down by the body and transformed into autologous bone tissue and in doing so offer an ideal combination of stability, elasticity and bioabsorbability. In recent medical-scientific publications concerning various clinical applications, MAGNEZIX® implants are rated as “being advantageous” or even “clinically superior” to conventional titanium implants.

Syntellix AG is the world’s market and technology leader in the field of bioabsorbable metallic orthopaedic implants and has already been honoured with numerous important awards and prizes, including the Innovation Award of the German Economy 2012/13, the Future Award 2016 of the German Healthcare Economy, the German Medical Award 2017, the STEP Award 2017, the Innovator of the Year 2017 award and the German Innovation Award in Gold (2019); internationally, the implants were a winner in the Product of the Year category of the Sustainability Award 2018 program.